Ingles Markets (IMKTA) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
7 May, 2026Executive summary
Net income for Q2 2026 was $24.3M, up from $15.1M in Q2 2025, driven by higher gross profit and vendor income despite lower sales and increased expenses.
Net sales for Q2 2026 decreased 1.8% year-over-year to $1.31B, impacted by Medicare drug price changes and ongoing store closures from Hurricane Helene; first half sales rose 2.4% to $2.68B.
For the six months ended March 28, 2026, net income rose to $52.4M from $31.7M year-over-year.
Basic EPS for Class A shares was $1.31 in Q2 2026, up from $0.81 in Q2 2025; six-month EPS was $2.82 vs. $1.70 year-over-year.
Financial highlights
Q2 2026 gross profit increased 4.6% to $325.3M, with gross margin rising to 24.9% from 23.4% year-over-year.
Operating and administrative expenses for Q2 2026 were $291.2M, nearly flat year-over-year.
Interest expense decreased to $4.5M in Q2 2026 from $4.9M in Q2 2025; first half interest expense was $9.1M, down from $9.9M.
Cash from operations for the six months ended March 28, 2026 was $122.2M, up from $19.4M year-over-year.
Capital expenditures for the first half were $53.0M, down from $62.0M year-over-year.
Outlook and guidance
Capital expenditures for fiscal 2026 are planned at $120–$140M, focusing on store improvements, reopening hurricane-damaged stores, and technology upgrades.
Three stores remain temporarily closed due to hurricane damage but are expected to reopen during 2026 and 2027.
Management expects current liquidity and financing resources to be sufficient for foreseeable capital and working capital needs.
Forward-looking statements highlight expectations for continued operational and financial performance, subject to economic and industry risks.
Latest events from Ingles Markets
- Contested annual meeting urges support for two independent director nominees and highlights key risks.IMKTA
Proxy filing27 Apr 2026 - Contested board election highlights risks and urges support for board nominees Jacobs and Lowe.IMKTA
Proxy filing23 Apr 2026 - Proxy contest urges support for independent nominees, citing risks from Sackler affiliation.IMKTA
Proxy filing20 Apr 2026 - Proxy contest highlights board's push for independent nominees and warnings over Sackler ties.IMKTA
Proxy filing20 Apr 2026 - Shareholders are urged to elect Lowe and Jacobs, rejecting Held over independence concerns.IMKTA
Proxy filing17 Apr 2026 - Contested proxy vote centers on board control, real estate strategy, and long-term value.IMKTA
Proxy filing16 Apr 2026 - Board urges support for independent nominees, citing risks from Sackler-affiliated candidate.IMKTA
Proxy filing13 Apr 2026 - Board urges voting for its nominees, citing major risks from Sacklers' Summer Road involvement.IMKTA
Proxy filing10 Apr 2026 - Contested proxy urges support for company nominees, citing major risks with Summer Road.IMKTA
Proxy filing10 Apr 2026